Edesa Biotech Inc.

2.03+0.0100+0.50%Vol 65.26K1Y Perf -55.70%
Aug 11th, 2022 15:59 DELAYED
BID2.02 ASK2.11
Open2.04 Previous Close2.02
Pre-Market- After-Market2.11
 - -  0.08 3.94%
Target Price
16.33 
Analyst Rating
Strong Buy 1.00
Potential %
704.43 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★     51.29
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★+     49.78
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
6.79 
Earnings Rating
Market Cap31.39M 
Earnings Date
12th Aug 2022
Alpha-0.03 Standard Deviation0.26
Beta0.91 

Today's Price Range

2.012.16

52W Range

1.3012.00

5 Year PE Ratio Range

-5.50-1.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-5.58%
1 Month
11.54%
3 Months
10.93%
6 Months
-47.81%
1 Year
-55.70%
3 Years
-53.33%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EDSA2.030.01000.50
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-362.80
-2 346 000.00
-2 322 230.00
-1 825.60
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-43.85
-9.56
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.37-0.3310.81
Q01 2022-0.40-0.3317.50
Q04 2021-0.37-0.2727.03
Q03 2021-0.32-0.36-12.50
Q02 2021-0.30-0.1936.67
Q01 2021-0.19-0.26-36.84
Q04 2020-0.21-0.22-4.76
Q03 2020-0.21-0.204.76
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2022
Estimated EPS Next Report-0.36
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume65.26K
Shares Outstanding15.46K
Shares Float7.88M
Trades Count468
Dollar Volume136.03K
Avg. Volume112.53K
Avg. Weekly Volume192.01K
Avg. Monthly Volume80.46K
Avg. Quarterly Volume65.11K

Edesa Biotech Inc. (NASDAQ: EDSA) stock closed at 2.03 per share at the end of the most recent trading day (a 0.5% change compared to the prior day closing price) with a volume of 65.26K shares and market capitalization of 31.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Edesa Biotech Inc. CEO is Pardeep Nijhawan.

The one-year performance of Edesa Biotech Inc. stock is -55.7%, while year-to-date (YTD) performance is -63.94%. EDSA stock has a five-year performance of %. Its 52-week range is between 1.3035 and 12, which gives EDSA stock a 52-week price range ratio of 6.79%

Edesa Biotech Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.49, a price-to-sale (PS) ratio of 470.04, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -80.76%, a ROC of -95.38% and a ROE of -98.76%. The company’s profit margin is -%, its EBITDA margin is -2 322 230.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Edesa Biotech Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. Edesa Biotech Inc.’s next earnings report date is 12th Aug 2022.

The consensus rating of Wall Street analysts for Edesa Biotech Inc. is Strong Buy (1), with a target price of $16.33, which is +704.43% compared to the current price. The earnings rating for Edesa Biotech Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Edesa Biotech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Edesa Biotech Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.56, ATR14 : 0.18, CCI20 : 110.63, Chaikin Money Flow : -0.14, MACD : 0.09, Money Flow Index : 67.78, ROC : 20.83, RSI : 53.90, STOCH (14,3) : 47.19, STOCH RSI : 0.56, UO : 48.01, Williams %R : -52.81), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Edesa Biotech Inc. in the last 12-months were: Michael Brooks (Buy at a value of $25 721), Pardeep Nijhawan (Buy at a value of $109 421)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

CEO: Pardeep Nijhawan

Telephone: +1 905 475-1234

Address: 100 Spy Court, Markham L3R 5H6, ON, CA

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

51%49%

Bearish Bullish

57%43%


News

Stocktwits